FDA presses in post-heparin era for more harmonized, QbD-aligned compendia
This article was originally published in The Gold Sheet
Executive Summary
A couple of FDA working groups are talking with the U.S. Pharmacopeia about how to better harmonize standards among USP and the European and Japanese pharmacopoeia, FDA's Helen Winkle said in response to a question about a lack of harmonization in their responses to last year's heparin crisis. She told the ISPE Washington conference June 1 that "one of the issues is that as we're changing to quality by design, USP is not changing with us.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.